2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes

“We at AstraZeneca are very pleased with the latest development with the AHA/ACC guideline recognizing ticagrelor as the preferred drug over the current standard of care in the treatment of NSTE-ACS patients undergoing a broad range of treatment strategies.”

“What we're now saying is that a physician who chooses a conservative strategy is not a pariah. It's an acceptable strategy, except for unstable patients.”